These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 7543497

  • 21. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases.
    Matsui T, Kurokawa M, Kobata T, Oki S, Azuma M, Tohma S, Inoue T, Yamamoto K, Nishioka K, Kato T.
    J Immunol; 1999 Apr 01; 162(7):4328-35. PubMed ID: 10201965
    [Abstract] [Full Text] [Related]

  • 22. CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.
    Freeman GJ, Lombard DB, Gimmi CD, Brod SA, Lee K, Laning JC, Hafler DA, Dorf ME, Gray GS, Reiser H.
    J Immunol; 1992 Dec 15; 149(12):3795-801. PubMed ID: 1281186
    [Abstract] [Full Text] [Related]

  • 23. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
    Via CS, Rus V, Nguyen P, Linsley P, Gause WC.
    J Immunol; 1996 Nov 01; 157(9):4258-67. PubMed ID: 8892665
    [Abstract] [Full Text] [Related]

  • 24. Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis.
    Perrin PJ, Scott D, Quigley L, Albert PS, Feder O, Gray GS, Abe R, June CH, Racke MK.
    J Immunol; 1995 Feb 01; 154(3):1481-90. PubMed ID: 7529805
    [Abstract] [Full Text] [Related]

  • 25. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
    Ruderman EM, Pope RM.
    Arthritis Res Ther; 2005 Feb 01; 7 Suppl 2(Suppl 2):S21-5. PubMed ID: 15833145
    [Abstract] [Full Text] [Related]

  • 26. Activation of CD4+ T cells by delivery of the B7 costimulatory signal on bystander antigen-presenting cells (trans-costimulation).
    Ding L, Shevach EM.
    Eur J Immunol; 1994 Apr 01; 24(4):859-66. PubMed ID: 7512033
    [Abstract] [Full Text] [Related]

  • 27. Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 molecule.
    Chen C, Gault A, Shen L, Nabavi N.
    J Immunol; 1994 May 15; 152(10):4929-36. PubMed ID: 7513726
    [Abstract] [Full Text] [Related]

  • 28. CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses.
    Onodera K, Chandraker A, Schaub M, Stadlbauer TH, Korom S, Peach R, Linsley PS, Sayegh MH, Kupiec-Weglinski JW.
    J Immunol; 1997 Aug 15; 159(4):1711-7. PubMed ID: 9257832
    [Abstract] [Full Text] [Related]

  • 29. CTLA-4 (CD152) inhibits the specific lysis mediated by human cytolytic T lymphocytes in a clonally distributed fashion.
    Saverino D, Tenca C, Zarcone D, Merlo A, Megiovanni AM, Valle MT, Manca F, Grossi CE, Ciccone E.
    J Immunol; 1999 Jan 15; 162(2):651-8. PubMed ID: 9916682
    [Abstract] [Full Text] [Related]

  • 30. Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation.
    Tao X, Constant S, Jorritsma P, Bottomly K.
    J Immunol; 1997 Dec 15; 159(12):5956-63. PubMed ID: 9550393
    [Abstract] [Full Text] [Related]

  • 31. Embryonic stem cells and embryoid bodies express lymphocyte costimulatory molecules.
    Ling V, Munroe RC, Murphy EA, Gray GS.
    Exp Cell Res; 1998 May 25; 241(1):55-65. PubMed ID: 9633513
    [Abstract] [Full Text] [Related]

  • 32. Blockade of T cell costimulation by CTLA4-Ig inhibits lung inflammation in murine hypersensitivity pneumonitis.
    Israël-Assayag E, Fournier M, Cormier Y.
    J Immunol; 1999 Dec 15; 163(12):6794-9. PubMed ID: 10586079
    [Abstract] [Full Text] [Related]

  • 33. B70 antigen is a second ligand for CTLA-4 and CD28.
    Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C.
    Nature; 1993 Nov 04; 366(6450):76-9. PubMed ID: 7694153
    [Abstract] [Full Text] [Related]

  • 34. Evidence that induction of tolerance in vivo involves active signaling via a B7 ligand-dependent mechanism: CTLA4-Ig protects V beta 8+ T cells from tolerance induction by the superantigen staphylococcal enterotoxin B.
    Lane P, Haller C, McConnell F.
    Eur J Immunol; 1996 Apr 04; 26(4):858-62. PubMed ID: 8625979
    [Abstract] [Full Text] [Related]

  • 35. The B7-CD28 superfamily.
    Sharpe AH, Freeman GJ.
    Nat Rev Immunol; 2002 Feb 04; 2(2):116-26. PubMed ID: 11910893
    [Abstract] [Full Text] [Related]

  • 36. Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7.
    Damle NK, Klussman K, Leytze G, Myrdal S, Aruffo A, Ledbetter JA, Linsley PS.
    J Immunol; 1994 Mar 15; 152(6):2686-97. PubMed ID: 7511623
    [Abstract] [Full Text] [Related]

  • 37. High concentrations of antigenic ligand activate and do not tolerize naive CD4 T cells in the absence of CD28/B7 costimulation.
    Teh HS, Teh SJ.
    Cell Immunol; 1997 Jul 10; 179(1):74-83. PubMed ID: 9259774
    [Abstract] [Full Text] [Related]

  • 38. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors.
    Greenfield EA, Howard E, Paradis T, Nguyen K, Benazzo F, McLean P, Höllsberg P, Davis G, Hafler DA, Sharpe AH, Freeman GJ, Kuchroo VK.
    J Immunol; 1997 Mar 01; 158(5):2025-34. PubMed ID: 9036945
    [Abstract] [Full Text] [Related]

  • 39. Expression and contribution of B7-1 (CD80) and B7-2 (CD86) in the early immune response to Leishmania major infection.
    Elloso MM, Scott P.
    J Immunol; 1999 Jun 01; 162(11):6708-15. PubMed ID: 10352289
    [Abstract] [Full Text] [Related]

  • 40. The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor.
    Freeman GJ, Cardoso AA, Boussiotis VA, Anumanthan A, Groves RW, Kupper TS, Clark EA, Nadler LM.
    J Immunol; 1998 Sep 15; 161(6):2708-15. PubMed ID: 9743327
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.